Discussion by HMPC Drafting Group on Quality September Start of public consultation 15 February 2013

Similar documents
Discussion by HMPC Drafting Group on Quality February Start of public consultation 27 June 2012

Draft agreed by HMPC Quality Drafting Group October Adopted by HMPC 12 November 2013

European Medicines Agency COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Guideline on quality of herbal medicinal products 1 /traditional herbal medicinal products

Guideline on quality of herbal medicinal products 2 /traditional herbal medicinal products

Discussion at the HMPC January March Draft agreed by Quality Working Party April Adoption by CHMP for release for consultation 26 May 2005

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

QUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS

Organisations and/or individuals

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL PROCEDURE FOR THE PREPARATION OF COMMUNITY MONOGRAPHS FOR TRADITIONAL HERBAL MEDICINAL PRODUCTS

QUALITY OF HERBAL REMEDIES

Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON EQUISETUM ARVENSE L., HERBA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., HERBA

Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

European Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON PASSIFLORA INCARNATA L., HERBA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Overview of comments received on Community herbal monograph on Cucurbita pepo L, semen (EMA/HMPC/136024/2010)

list (MLWP) September 2009 January 2010

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

Potential Grounds for Revocation of a Traditional Herbal Registration

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Community herbal monograph on Olea europaea L., folium

Community herbal monograph on Cynara scolymus L., folium

Community herbal monograph on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SOLIDAGO VIRGAUREA L., HERBA

Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma

Prof.Dr.Theodor Dingermann, Institut für Pharmazeutische Biologie, Goethe-Universität Frankfurt a.m.

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PALLIDA (NUTT.) NUTT., RADIX

Community herbal monograph on Eucalyptus globulus Labill., folium

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Guideline on the demonstration of palatability of veterinary medicinal products

OVERVIEW OF COMMENTS RECEIVED ON COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA L., FOLIUM (EMEA/HMPC/114586/2008)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON RUSCUS ACULEATUS L., RHIZOMA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON BETULA PENDULA ROTH; BETULA PUBESCENS EHRH.

Community herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

Community herbal monograph on Achillea millefolium L., flos

H e r b a l M e dicines' Q U A L I T Y M ANUAL. I. Introduction

Community herbal monograph on Rhodiola rosea L., rhizoma et radix

Community herbal monograph on Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum

Agreed by Gastroenterology Drafting Group May Adopted by CHMP for release for consultation 24 May Start of public consultation 8 June 2012

Community herbal monograph on Cinnamomum verum J.S. Presl (Cinnamomum zeylanicum Nees), aetheroleum

Community herbal monograph on Symphytum officinale L., radix

Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore

End of consultation (deadline for comments) 15 August 2012 Rediscussion in Working Party on Community monographs and Community list (MLWP)

European Medicines Agency. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SALVIA OFFICINALIS L.

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VALERIANA OFFICINALIS L., RADIX AND HUMULUS LUPULUS L.

Guideline on influenza vaccines submission and procedural requirements

Community herbal monograph on Olea europaea L., folium. November 2009 list (MLWP)

Questions & answers on quality of herbal medicinal products/traditional herbal medicinal products 1

European Medicines Agency Inspections

Community herbal monograph on Agrimonia eupatoria L., herba

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON THYMUS VULGARIS L. AND THYMUS ZYGIS L., HERBA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON MELILOTUS OFFICINALIS (L.) LAM., HERBA

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

VICH GL58 Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALTHAEA OFFICINALIS L., RADIX

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON

Community herbal monograph on Panax ginseng C.A.Meyer, radix

Community herbal monograph on Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

Public Assessment Report Scientific discussion

Community herbal monograph on Cichorium intybus L., radix

Concept paper on a Guideline for allergen products development in moderate to low-sized study populations

Superseded. Community herbal monograph on Ribes nigrum L., folium. Adoption by Committee on Herbal Medicinal Products (HMPC) 6 May 2010

Community herbal monograph on Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium

Community herbal monograph on Aesculus hippocastanum L., cortex

European Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Good pharmacopoeial practices: Chapter on monographs on herbal medicines

1 March 2010 EMA/131300/2010 Human Medicines Development and Evaluation. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom

Community herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Community herbal monograph on Marrubium vulgare L., herba

Superseded. Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizoma

AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS

Authorisation and registration of Herbal medicinal products and traditional herbal medicinal products. National and Community regulation.

Superseded. Community herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix. September 2010 list (MLWP)

Meeting report, September 2005

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON ILEX PARAGUARIENSIS ST. HIL., FOLIUM

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Draft Agreed by Biosimilar Working Party (BMWP) October Adoption by CHMP for release for consultation 17 November 2011

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA L., FOLIUM

European Medicines Agency decision

Public Assessment Report Scientific discussion. Echinaforce Forte, tablet. Asp. No:

Overview of comments received on Community herbal monograph on Leonurus cardiaca L., herba (EMA/HMPC/561942/2010)

Community herbal monograph on Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos

Transcription:

1 2 3 15 January 2013 EMA/HMPC/13658/2013 Committee on Herbal Medicinal Products (HMPC) 4 5 6 7 Concept paper on use of recovered/recycled solvents in the manufacture of herbal preparations for use in herbal medicinal / traditional herbal medicinal Discussion by HMPC Drafting Group on Quality September 2012 December 2012 Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation 15 January 2013 Start of public consultation 15 February 2013 End of consultation (deadline for comments) 15 May 2013 Agreed by HMPC Quality Drafting Group Adopted by HMPC Comments should be provided using this template. The completed comments form should be sent to hmpc.secretariat@ema.europa.eu Keywords HMPC; herbal medicinal ; traditional herbal medicinal ; herbal substances; herbal preparations; herbal extracts, recycled/recovered solvents 8 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

9 10 11 12 Concept paper on use of recovered/recycled solvents in the manufacture of herbal preparations for use in herbal medicinal / traditional herbal medicinal 13 14 15 16 17 18 19 20 21 22 23 24 25 Table of contents 1. Introduction... 3 2. Scope... 3 3. Problem statement... 3 4. Discussion... 3 5. Recommendation... 5 6. Timetable... 5 7. Resource requirements for preparation... 5 8. Impact assessment (anticipated)... 5 9. Interested parties... 5 10. Definitions... 5 11. References... 6 26 preparations for use in herbal medicinal / traditional herbal medicinal EMA/HMPC/13658/2013 Page 2/6

27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 1. Introduction This concept paper concerns the standards to be applied to recycled/recovered solvents used for extraction of herbal substances in the manufacture of herbal preparations for use in herbal medicinal (HMPs) / traditional herbal medicinal (THMPs). The quality of herbal medicinal should be guaranteed and demonstrated in accordance with the existing requirements as set out in Annex I of Directive 2001/83/EC, as amended, with specific herbal quality guidelines such as Guideline on quality of HMPs/THMPs (EMA/CPMP/QWP/2819/00 Rev. 2) (EMA/CVMP/814/00 Rev. 2), Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and HMPs/THMPs (EMA/CPMP/QWP/2820/00 Rev. 2) (EMA/CVMP/815/00 Rev. 2), Guideline on quality of combination HMPs/THMPs (EMEA/HMPC/CHMP/CVMP/214869/2006) and, in addition, with current EU/ICH general quality guidelines for medicinal that are applicable to HMPs/THMPs. Recycled/recovered solvents are widely used for extraction of herbal substances in the manufacture of herbal preparations for use in HMPs / THMPs. The quality of the recycled/recovered solvents is a critical factor in controlling the quality of the resulting herbal preparations and ensuring batch to batch reproducibility. The purpose of the proposed guideline is to identify the criteria to be taken into account when establishing standards/specifications for recycled/recovered solvents in the manufacture of herbal preparations and to provide guidance on the documentation needed to demonstrate that they are adequately controlled and suitable for their intended purpose. 2. Scope The concepts described in the proposed guideline will be applicable to registration applications for THMPs for human use and will also be applicable to marketing authorisation applications for HMPs for human and veterinary use. 3. Problem statement Recycled/recovered solvents are widely used for extraction of herbal substances in the manufacture of herbal preparations for use in HMPs / THMPs. The quality of the recycled/recovered solvents is a critical factor in controlling the quality of the resulting herbal preparations and ensuring batch to batch reproducibility. Existing guidelines provide only limited guidance on the standards/specifications to be applied to recycled/recovered solvents. As a result, the supporting documentation provided varies between applicants/manufacturers, even for similar. 4. Discussion The majority of herbal preparations used in HMPs / THMPs are herbal extracts. Whilst many herbal extracts are prepared using water a substantial number involve the use of organic solvents, primarily alcoholic extracts (ethanol, methanol), but also acetone, ethyl acetate etc may be employed. Furthermore, in many cases, solvents are used during the processing, such as preliminary defatting of the herbal substance, for example, with hexane or during purification, refining steps when solvents such as dichloromethane may be employed. preparations for use in herbal medicinal / traditional herbal medicinal EMA/HMPC/13658/2013 Page 3/6

66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 Current guidance on GMP for active pharmaceutical ingredients (APIs) sets out basic requirements for active substances and recognises that the use of recovered solvents is acceptable with the caveats that approved procedures for the recovery exist and that the recovered materials meet specifications suitable for their intended use. Recovery of Materials and Solvents Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before reuse or co-mingling with other approved materials. Fresh and recovered solvents and reagents can be combined if adequate testing has shown their suitability for all manufacturing processes in which they may be used. The use of recovered solvents, mother liquors, and other recovered materials should be adequately documented. The European Pharmacopoeia likewise recognises that for extracts where the organic solvent is removed, recovered or recycled solvent may be used, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before re-use or admixture with other approved materials. However, existing guidelines provide only limited guidance on the standards/specifications to be applied to recycled/recovered solvents and this does not address the particular nature of herbal preparations and their complexity. As a result, the supporting documentation provided varies between applicants/manufacturers, even for similar. Further consideration should be given to documentation needed to demonstrate that the recycled/recovered solvents meet acceptable standards for the manufacture of herbal preparations. This should include discussion of issues relating to the methods used for recovery, stage at which solvents are recovered (e.g. in-process or final stage evaporation), acceptability of pooling of solvents from different extraction procedures, and should address the potential for cross-contamination as well as the validation data required to support the usage. In some cases, special provisions may need to apply, for example where solvents are used to remove unwanted, potentially toxic constituents, pooling of recovered solvents with other solvents may not be acceptable. Recovery operations should be described in detail and handling of solvent mixtures should be addressed. Details of any processing (e.g. rectification) to improve the quality of the recovered solvent should be described. Recovered solvents need to be adequately controlled such that constituents from previous extractions or impurity levels, including potential contaminants such as pesticides, fumigants, mycotoxins, do not concentrate up or increase over time. Suitable specifications should be applied to the recovered solvents. In cases where the herbal preparation is a liquid extract/tincture and the extraction solvent remains as part of the preparation and is not removed (cf. dry extracts/soft extracts), the use of recovered/recycled solvent (mainly ethanol) should be avoided unless fully justified and appropriate standards are applied. A guideline on the standards to be applied to recycled/recovered solvents used in the manufacture of herbal preparations should describe in detail the documentation that the applicant should provide in order to demonstrate that the solvents are adequately characterised and meets quality standards appropriate for their intended use. preparations for use in herbal medicinal / traditional herbal medicinal EMA/HMPC/13658/2013 Page 4/6

108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 5. Recommendation As there is very little information on standards to be applied to recycled/recovered solvents used for extraction of herbal substances in the existing guidelines, the HMPC recommends the development of a respective guideline. A guideline on standards to be applied to recycled/recovered solvents used for extraction herbal substances should describe the information to be provided in Module 3 section 3.2.S.2.3 Control of Materials. This guideline shall apply to THMPs for human use and to HMPs both for human and veterinary use. 6. Timetable It is anticipated that a draft guideline could be available one year after publication of the concept paper. The draft guideline will be released for external consultation for six months. The guideline could be finalised within six months after external consultation. 7. Resource requirements for preparation The Rapporteur and Co-Rapporteur should prepare a draft guideline. Members States are invited to provide comments via their Committee and/or Working Party Members. 8. Impact assessment (anticipated) The development of this guideline on standards to be applied to recycled/recovered solvents used for extraction of herbal substances in the manufacture of herbal preparations is expected to benefit industry. When recycled/recovered solvents used for extraction need to be used, this guideline will clarify the information to be submitted in Module 3 (section 3.2.S.2.3 Control of Materials). This will therefore provide benefits to applicants in the preparation of their applications. The guideline is also expected to help competent authorities when assessing applications by harmonising requirements and thus enabling a more consistent approach to assessment of the documentation. 9. Interested parties During the consultation period on the draft guideline, comments from parties concerned with the use of THMPs and HMPs will be welcome. 10. Definitions Herbal medicinal : any medicinal product, exclusively containing as active substances one or more herbal substances or one or more herbal preparations, or one or more such herbal substances in combination with one or more such herbal preparations. Herbal preparations: are obtained by subjecting herbal substances to treatments such as extraction, distillation, expression, fractionation, purification, concentration or fermentation. These include comminuted or powdered herbal substances, tinctures, extracts, essential oils, expressed juices and processed exudates. preparations for use in herbal medicinal / traditional herbal medicinal EMA/HMPC/13658/2013 Page 5/6

143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 Herbal substances: all mainly whole, fragmented or cut plants, plant parts, algae, fungi, lichen in an unprocessed, usually dried form but sometimes fresh. Certain exudates that have not been subjected to a specific treatment are also considered to be herbal substances. Herbal substances are precisely defined by the plant part used and the botanical name according to the binomial system (genus, species, variety and author). Specification: A list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. It establishes the set of criteria to which a herbal substance/preparation or herbal medicinal product should conform to be considered acceptable for its intended use. "Conformance to specifications" means that the herbal substance/preparation and/or herbal medicinal product, when tested according to the listed analytical procedures, will meet the listed acceptance criteria. Specifications are binding quality standards that are agreed to between competent regulatory authorities and applicants. Traditional herbal medicinal : are medicinal for human use that fulfil the conditions laid down in article 16a (1) of Directive 2001/83/EC, as amended. 11. References Guideline on quality of herbal medicinal /traditional herbal medicinal (EMA/CPMP/QWP/2819/00 Rev. 2), (EMA/CVMP/814/00 Rev. 2) Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal /traditional herbal medicinal (EMA/CPMP/QWP/2820/00 Rev. 2), (EMA/CVMP/815/00 Rev. 2) Guideline on quality of combination herbal medicinal / traditional herbal medicinal (EMEA/HMPC/CHMP/CVMP/214869/2006) European Pharmacopoeia General Monograph Extracts 04/2008:0765 ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (CPMP/ICH/4106/00) preparations for use in herbal medicinal / traditional herbal medicinal EMA/HMPC/13658/2013 Page 6/6